Skip to main content
Log in

Interim analyses suggest that aprotinin is associated with an increased risk of death

  • Media release
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

REFERENCE

  1. FDA.Early communication about an ongoing safety review aprotinin injection (marketed as Trasylol). Internet Document: [2 pages], 19 Oct 2007. Available from: URL: http://www.fda.gov

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Interim analyses suggest that aprotinin is associated with an increased risk of death. React. Wkly. 1176, 2 (2007). https://doi.org/10.2165/00128415-200711760-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-200711760-00004

Keywords

Navigation